Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus MARCAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE VISCOUS versus MARCAINE HYDROCHLORIDE.
LIDOCAINE HYDROCHLORIDE VISCOUS vs MARCAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and propagation of action potentials. It also has antiarrhythmic properties (Class Ib) by accelerating repolarization and reducing automaticity in cardiac tissues.
Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, reversibly inhibiting nerve impulse propagation, particularly in sensory fibers.
Adult: 15 mL (300 mg) orally every 3 hours, not to exceed 8 doses in 24 hours. Viscous formulation swished and swallowed.
Adults: 0.5% solution infiltrated up to 175 mg (35 mL) for minor procedures; for major procedures, up to 225 mg (45 mL) with epinephrine. Repeat doses at 3-hour intervals. Maximum dose 400 mg with epinephrine.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours (adults); prolonged in heart failure (2.5–4 hours) or hepatic disease (up to 5–7 hours). Context: short t1/2 limits toxic accumulation with topical use.
Terminal elimination half-life is approximately 2.5 to 3.5 hours in adults; may be prolonged in neonates (8-12 hours) or patients with hepatic impairment.
Renal: ~90% as metabolites (mainly 4-hydroxy-2,6-xylidine and glucuronides), <10% unchanged. Biliary/fecal: minor (<5%).
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Metabolites are excreted renally, with a small amount in feces via biliary elimination.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic